Systematic review reveals short-term benefits of SGAs in youth with schizophrenia-spectrum disorders, highlighting a need for more long-term studies.
Several SGAs produce short-term symptom reductions versus placebo in children and adolescents with schizophrenia-spectrum disorders, with heterogeneity in TEAE risk across agents. Evidence for long-term maintenance and continuation remains limited, underscoring the need for adequately powered randomized continuation trials to guide sustained treatment in this population.
No takes yet. Share an insight, caveat, or question.
Vázquez et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: